PYPD

PolyPid Ltd. is a late-stage clinical biopharmaceutical company focused on developing targeted, localized therapies to prevent and treat infections. Headquartered in Petach Tikva, Israel, the company specializes in its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology platform, which enables extended, controlled release of drugs directly at the site of treatment. PolyPid's lead product candidate, D-PLEX100, is designed to prevent surgical site infections following abdominal surgery by providing sustained release of doxycycline over four weeks. The company completed its Phase 3 SHIELD I trial evaluating D-PLEX100 in soft tissue surgeries and is advancing the product through regulatory pathways. In October 2022, PolyPid received FDA Qualified Infectious Disease Product (QIDP) designation for D-PLEX100, which grants eligibility for priority review and extended market exclusivity upon approval. The company went public on NASDAQ in January 2021 through a merger with a special purpose acquisition company. PolyPid maintains research and development operations in Israel while pursuing partnerships and regulatory approvals in multiple markets. The company's pipeline also includes D-PLEX500, an earlier-stage candidate utilizing the same platform technology for additional therapeutic applications. As of recent filings, PolyPid employs approximately 30 people and focuses its resources on advancing its lead asset toward potential commercialization.